When a company raises money, either an initial public offering or follow-up offering, the offering may include DRs. The inclusion of DRs may broaden the shareholder base of the company.

BNY Mellon collects fees from DR holders pursuant to the terms and conditions of the DRs and the deposit agreement under which they are issued. From time to time, BNY Mellon may make payments to the issuer to reimburse and / or share revenue from the fees collected from DR holders, or waive fees and expenses to the issuer for services provided, generally relating to costs and expenses arising out of establishment and maintenance of the DR program. BNY Mellon as depositary may use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

Ratio
DR:Ord
DR Price
Date
DR Price
(USD)
US / Non-US / Total DRs Placed US / Non-US / Total DR Captial Raised (USD) Pvtzn. Dep. Bank Industry Country Region
53:4 Apr 30, 2015 9.00 3,321,669
0
3,321,669
29,895,021
0
29,895,021
N CIT Pharma. & Biotech. Germany Continental Europe
53:4 Sep 12, 2014 9.00 186,984
0
186,984
1,682,856
0
1,682,856
N CIT Pharma. & Biotech. Germany Continental Europe
53:4 Jul 25, 2014 9.00 6,499,973
0
6,499,973
58,499,757
0
58,499,757
N CIT Pharma. & Biotech. Germany Continental Europe

Powered by FactSet Research Systems Inc.